Table 2: Baseline characteristics in the two groups of peginterferon α-2a and peginterferon α-2b in this meta-analysis.

StudyPeginterferon groupTotal patientsMean
age (years)
Gender (male/female)HCV genotype (1/2/3/4)F3-4 OR cirrhosis, (%)Body weight (kg)BMI (kg/m2)

Yenice et al. [5]α-2a3749.9513/2437/0/0/0NANANA
α-2b3750.8410/2737/0/0/0NANANA
Di Bisceglie et al.
[6]
α-2a18946.9 ± 0.52121/68189/0/0/028 (14.8)86.5 ± 1.3429.2 ± 0.44
α-2b19148.4 ± 0.56136/55191/0/0/029 (15.2)85.4 ± 1.3228.5 ± 0.42
Scotto et al. [7]α-2a7145.86 ± 9.3342/2945/6/8/1213 (18.3)80.718.5–24.9 ( ), 25–29.9 ( ), ≥30 ( )
α-2b7247.82 ± 9.6140/3247/5/9/1113 (18.1)78.918.5–24.9 ( ), 25–29.9 ( ), ≥30 ( )
McHutchison et al. [8]α-2a103547.6 ± 8.2613/4221035/0/0/0110 (10.6)82.8 ± 16.6NA
α-2b101947.5 ± 7.8613/4061019/0/0/0111 (10.9) 84.0 ± 16.5NA
Rumi et al. [9]α-2a21251.6 ± 12.0128/8491/69/34/1843 (20.3)72.2 ± 14.625.5 ± 4.4
α-2b21952.8 ± 12.0120/9987/74/32/2639 (17.8)68.9 ± 12.024.8 ± 3.7
Ascione et al. [10]α-2a16051.3 ± 10.381/7989/49/18/433 (20.6)70.4 ± 10.625.5 ± 3.1
α-2b16048.9 ± 11.394/6692/50/17/126 (16.3)69.9 ± 10.725.3 ± 3.0
Mach et al. [11]α-2a13845.2 ± 10.580/58138/0/0/013 (9.4)NA24.5 ± 0.9
α-2b12244.2 ± 13.673/49122/0/0/012 (9.8)NA25.1 ± 1.3

NA: not available; BMI: Body mass index; Ishak score S5, 6.
F0–4 (F0: no fibrosis; F1: portal fibrosis without septa; F2: portal fibrosis with few septa; F3: numerous septa without cirrhosis; F4: cirrhosis).
All baseline characteristics were comparative between the two groups.